Study looks at the ability of some monkey species to resist developing AIDS

The Tulane National Primate Research Center received a five-year grant of more than $2 million from the National Institute of Allergy and Infectious Diseases to study the ability of some monkey species to resist developing AIDS.

The study seeks to answer the question of how African green monkeys, when infected with SIV (simian immunodeficiency virus, the monkey equivalent of HIV) are resistant to the development of AIDS, compared to humans and other monkeys.

"The host and virus seem to have developed a relationship over time, through evolution, so the infection isn't as harmful to this type of monkey as it is in other monkeys such as the rhesus macaque," says Andrew Lackner, primate center director.

Scientists once thought natural hosts of SIV such as African green monkeys did not become sick with AIDS when infected with the virus, says Ivona Pandrea, principal investigator of the study. However, recent research shows that the natural hosts can progress to AIDS after a prolonged period of SIV infection without symptoms.

"While a rhesus monkey typically develops AIDS two to four years after infection," Pandrea says," and a human may not develop AIDS for five to 10 years after infection, the African monkeys may not develop AIDS for 20 years, if ever."

In previous work in Gabon, Central Africa, Pandrea studied infection in African green monkeys and mandrills. "We discovered that these monkeys harbor high viral loads, but there are very few cases of AIDS in this species, which may occur only after a very long incubation period, that generally exceeds the normal life span of these monkeys, at least in the wild," Pandrea says.

There have been very few studies with these monkeys that scientists call "long-term progressors," Pandrea says. She hopes that her work might help researchers enhance the human immune system so that HIV-positive people might be able to delay the onset of AIDS.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dietitians boost GLP-1 therapy success with personalized care and side effect management